In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

JCR Pharmaceuticals Co. Ltd.

www.jcrpharm.co.jp

Latest From JCR Pharmaceuticals Co. Ltd.

Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem

The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?

Japan Gene Therapy

Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem

The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?

Japan Gene Therapy

Approval Positions Roxadustat As Japan HIF-PHI Pioneer

The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.

Japan Approvals

Japan Approves Biosimilar Teriparatide And Darbepoetin

Japan’s first biosimilar teriparatide has been approved for Mochida Pharmaceutical, while competition in the darbepoetin alfa arena looks set to step up following two recent authorizations.

Biosimilars Japan
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • JCR Pharmaceuticals Co. Ltd.
  • Senior Management
  • Shin Ashida, Pres. & CEO
    Teiji Tomio, Dir., Clin. Dev. & R&D
  • Contact Info
  • JCR Pharmaceuticals Co. Ltd.
    Phone: (81) 797 32 8591
    3-19 Kasuga-Cho
    Ashiya City, 659-0021
    Japan
UsernamePublicRestriction

Register